Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 61559X104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. 13G | 5.3% |
8/14/2026
Event 6/30/2026
|
|
|
Cormorant Asset Management, LP
13G/A
Amendment 2
|
4.4% |
8/14/2026
Event 6/30/2026
|
|
| Cormorant Asset Management, LP | 4.4% | ||
| Bihua Chen | 4.4% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
9.7% |
8/14/2026
Event 6/30/2026
|
|
| Deep Track Capital, LP | 9.7% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 9.7% | ||
| David Kroin | 9.7% | ||
|
Biotechnology Value Fund L P
13D/A
Amendment 6
|
19.7% |
6/29/2026
Event 6/25/2026
|
|
| Biotechnology Value Fund L P | 10.2% | ||
| BVF I GP LLC | 10.2% | ||
| Biotechnology Value Fund II LP | 8.1% | ||
| BVF II GP LLC | 8.1% | ||
| Biotechnology Value Trading Fund OS LP | 1.3% | ||
| BVF Partners OS Ltd. | 1.3% | ||
| BVF GP Holdings LLC | 18.4% | ||
| BVF Partners L P/IL | 19.7% | ||
| BVF Inc/IL | 19.7% | ||
| Lampert Mark N | 19.7% | ||
| Loy Spike | <0.1% | ||
|
Cormorant Asset Management, LP
13G/A
Amendment 1
|
6.3% |
5/15/2026
Event 3/31/2026
|
|
| Cormorant Asset Management, LP | 6.3% | ||
| Bihua Chen | 6.3% | ||
|
Biotechnology Value Fund L P
13D/A
Amendment 5
|
22.3% |
4/2/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 11.6% | ||
| BVF I GP LLC | 11.6% | ||
| Biotechnology Value Fund II LP | 9.2% | ||
| BVF II GP LLC | 9.2% | ||
| Biotechnology Value Trading Fund OS LP | 1.4% | ||
| BVF Partners OS Ltd. | 1.4% | ||
| BVF GP Holdings LLC | 20.8% | ||
| BVF Partners L P/IL | 22.3% | ||
| BVF Inc/IL | 22.3% | ||
| Lampert Mark N | 22.3% | ||
| Loy Spike | <0.1% | ||
|
Cormorant Asset Management, LP
13G
|
6.1% |
2/17/2026
Event 12/31/2025
|
|
| Cormorant Asset Management, LP | 6.1% | ||
| Bihua Chen | 6.1% | ||
|
Avoro Capital Advisors LLC
13G/A
Amendment 1
|
3.2% |
11/14/2025
Event 9/30/2025
|
|
| Avoro Capital Advisors LLC | 3.2% | ||
| Behzad Aghazadeh | 3.2% | ||
|
Deep Track Capital, LP
13G
|
6.5% |
11/12/2025
Event 11/5/2025
|
|
| Deep Track Capital, LP | 6.5% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 6.5% | ||
| David Kroin | 6.5% | ||
|
Biotechnology Value Fund L P
13D/A
Amendment 4
|
27.7% |
11/10/2025
Event 11/6/2025
|
|
| Biotechnology Value Fund L P | 14.3% | ||
| BVF I GP LLC | 14.3% | ||
| Biotechnology Value Fund II LP | 11.4% | ||
| BVF II GP LLC | 11.4% | ||
| Biotechnology Value Trading Fund OS LP | 1.8% | ||
| BVF Partners OS Ltd. | 1.8% | ||
| BVF GP Holdings LLC | 25.8% | ||
| BVF Partners L P/IL | 27.7% | ||
| BVF Inc/IL | 27.7% | ||
| Lampert Mark N | 27.7% | ||
| Loy Spike | <0.1% | ||
|
FMR LLC
13G/A
Amendment 4
|
1.1% |
11/5/2025
Event 9/30/2025
|
|
| FMR LLC | 1.1% | ||
| Abigail P. Johnson | 1.1% | ||
| Chen Bihua 13G/A Amendment 2 | 3.1% |
10/1/2025
Event 9/30/2025
|
|
|
Avoro Capital Advisors LLC
13G
|
6.5% |
8/14/2025
Event 6/30/2025
|
|
| Avoro Capital Advisors LLC | 6.5% | ||
| Behzad Aghazadeh | 6.5% | ||
|
FMR LLC
13G/A
Amendment 3
|
9.0% |
8/6/2025
Event 6/30/2025
|
|
| FMR LLC | 9.0% | ||
| Abigail P. Johnson | 9.0% | ||
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 1 | 4.7% |
5/14/2025
Event 3/31/2025
|
|
| Price T Rowe Associates Inc /MD/ 13G | 5.3% |
2/14/2025
Event 12/31/2024
|
|
|
FMR LLC
13G/A
Amendment 2
|
10.0% |
2/12/2025
Event 12/31/2024
|
|
| FMR LLC | 10.0% | ||
| Abigail P. Johnson | 10.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 224 k | $2.62 M |
| 2026 Q2 | 188 | 74.1 M | $1.47 B |
| 2026 Q1 | 161 | 63.3 M | $1.18 B |
| 2025 Q4 | 150 | 56.4 M | $743 M |
| 2025 Q3 | 174 | 37.6 M | $270 M |
| 2025 Q2 | 148 | 58.6 M | $2.77 B |
| 2025 Q1 | 154 | 60.1 M | $2.35 B |
| 2024 Q4 | 131 | 63.2 M | $3.42 B |
| 2024 Q3 | 119 | 62.1 M | $3.13 B |
| 2024 Q2 | 129 | 61.6 M | $2.71 B |
| 2024 Q1 | 141 | 59.9 M | $3.01 B |
| 2023 Q4 | 156 | 59.8 M | $3.56 B |
| 2023 Q3 | 136 | 56.5 M | $3.22 B |
| 2023 Q2 | 87 | 56.3 M | $2.87 B |
| 2023 Q1 | 44 | 39.4 M | $843 M |
| 2022 Q4 | 34 | 37.7 M | $396 M |
| 2022 Q3 | 25 | 36.9 M | $291 M |
| 2022 Q2 | 24 | 36.5 M | $190 M |
| 2022 Q1 | 1 | 654 k | $7.26 M |